Archive - Grasshopper Observer

January 2024

Genelux: Even the insiders are fleeing

A 20 year old unremarkable oncolytic viral immunotherapy company, IPO’d at the start of 2023 lacking any notable investors, questionable science, and…

Jan 17, 2024 •

Grasshopper Observer

Iridex: A Microcap Pump Whose Air Will Run Out

Iridex: A Microcap Pump Whose Air Will Run Out

Jan 12, 2024 •

Grasshopper Observer

Anavex: A Misallocation of Capital

Anavex is a pre-commercial biotech with no viable products, studies or seeming value save for its ability to issue equity at the market

Jan 10, 2024 •

Grasshopper Observer

#nojs-banner { position: fixed; bottom: 0; left: 0; padding: 16px 16px 16px 32px; width: 100%; box-sizing: border-box; background: red; color: white; font-family: -apple-system, "Segoe UI", Roboto, Helvetica, Arial, sans-serif, "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Symbol"; font-size: 13px; line-height: 13px; } #nojs-banner a { color: inherit; text-decoration: underline; } This site requires JavaScript to run correctly. Please turn on JavaScript or unblock scripts